Prenatal and postnatal genetic testing toward personalized care: The non-invasive perinatal testing

Mol Cell Probes. 2023 Dec:72:101942. doi: 10.1016/j.mcp.2023.101942. Epub 2023 Nov 16.

Abstract

This article investigates how non-invasive prenatal testing and the incorporation of genomic sequencing into newborn screening postnatally are transforming perinatal care. They improve the accuracy of prenatal and neonatal screening, allowing for early interventions and personalized therapies. Non-invasive prenatal testing before birth and saliva-sample-based newborn genomic sequencing after birth can be collectively referred to as non-invasive perinatal testing. Non-invasive prenatal testing is particularly useful for aneuploidy, whereas performance markers worsen as DNA abnormalities shrink in size. Screening for clinically actionable diseases in childhood would be crucial to personalized medical therapy, as the postnatal period remains appropriate for screening for the great majority of monogenic disorders. While genomic data can help diagnose uncommon diseases, challenges like ethics and equity necessitate joint approaches for appropriate integration in this revolutionary journey toward personalized care.

Keywords: NIPT; Newborn genomic sequencing; Newborn screening; Non-invasive perinatal testing; Non-invasive prenatal testing.

Publication types

  • Review

MeSH terms

  • Aneuploidy
  • Female
  • Genetic Testing*
  • Humans
  • Infant, Newborn
  • Pregnancy
  • Prenatal Diagnosis*